-
GPX4, GSH, and Wnt Signaling in Lung Cancer BM
2026-09-20
The reference study identifies a GPX4- and GSTM1-associated high-glutathione-consumption state as a driver of acquired platinum resistance in lung cancer-derived brain metastasis. Its integrated metabolomic, proteomic, and mechanistic experiments connect Wnt/NR2F2-dependent GPX4 transcription with ferroptosis suppression, providing a rationale for combining platinum treatment with GPX4-directed strategies.
-
Sodium Oxamate for LDH-A Metabolism Workflows
2026-09-19
Sodium Oxamate provides a water-soluble route to perturb LDH-A activity, lactate output, and glycolytic dependence without relying on DMSO. This guide translates that metabolic intervention into reproducible viability, lactate, and radiation-response workflows, with safeguards against mistaking upstream lactate reduction for direct inhibition of protein lactylation.
-
NIH/3T3 Cells: Recovery, Culture, and QC
2026-09-18
NIH/3T3 Cells provide a cryopreserved, adherent mouse fibroblast starting material for controlled expansion, cell transfection studies, viral proliferation research, and oncogene research. They should be used for research workflows under validated laboratory conditions, not as a diagnostic, medical, or quantitatively characterized clinical system.
-
Genistein Workflows for Mechanostress Autophagy
2026-09-18
Genistein connects growth-factor signaling with experimentally induced mechanical stress, enabling a practical two-axis design for studying autophagy, viability, and cancer-relevant phenotypes. This guide combines dose-aware cell workflows with cytoskeleton-focused controls, solvent safeguards, and troubleshooting boundaries.
-
Sodium Salicylate NF-κB Inhibitor Workflows
2026-09-17
Build reproducible inflammation, oxidative-stress, and stromal biology assays with Sodium salicylate as a soluble NF-κB inhibitor and pathway-control reagent. This guide connects practical cell-based workflows with the sequential, stroma-remodeling strategy reported in a recent pancreatic cancer nanomedicine study, while separating established findings from assay recommendations.
-
Ouabain Workflows for Na+/K+-ATPase Research
2026-09-17
Ouabain enables controlled interrogation of sodium-potassium pump activity, calcium handling, and cardiotonic steroid responses across cellular and cardiovascular models. This guide pairs mechanistic transport assays with viability and timing measurements to distinguish pump inhibition from nonspecific loss of cell fitness.
-
DiscoveryProbe FDA-approved Drug Library Workflows
2026-09-16
Turn clinically characterized compounds into mechanism-led screens with a practical workflow for interaction assays, phenotypic profiling, and hit confirmation. The DiscoveryProbe FDA-approved Drug Library combines 2,320 pre-dissolved compounds with assay-ready formats for faster drug repositioning screening and pharmacological target identification.
-
MHY1485 for Reliable mTOR and Autophagy Assays
2026-09-16
This scenario-based guide explains how MHY1485 (SKU B5853) can help researchers distinguish mTOR-driven changes in cell survival, proliferation, and autophagy from solvent or handling artifacts. It covers DMSO stock preparation, assay controls, LC3-II interpretation, and practical vendor-selection criteria.
-
Minocycline HCl and the Retina’s Clearance Axis
2026-09-15
Retinal amyloid clearance is emerging as a microglia-dependent translational endpoint. This article examines how Minocycline HCl functions as a mechanistic inhibitor in a 40-Hz light-flicker model, while providing practical guidance for experimental design, product handling, and interpretation.
-
Anti-b Targets mTOR Signaling in Hyperlipidaemia
2026-09-15
A 2025 British Journal of Pharmacology study shows that the low-molecular-weight compound Anti-b reduces diet- and oleic-acid-induced dyslipidaemia and hepatic steatosis in animal and cell models. Its central mechanistic finding is that Anti-b binds mTOR, alters its thermal stability and phosphorylation, and suppresses downstream PPARγ and SREBP1 lipid-synthesis signalling.
-
Reelin–SFK Signaling in Ketamine Synaptic Action
2026-09-14
This PNAS study identifies Reelin–ApoER2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal synaptic plasticity and behavioral effects. By combining genetic deletion, pharmacological inhibition, electrophysiology, and biochemical analysis, the authors show that disruption of this pathway compromises baseline NMDA receptor function and blocks ketamine responsiveness in mice.
-
NIH/3T3 Cells: Recovery, Culture, and QC
2026-09-14
NIH/3T3 Cells provide an adherent mouse fibroblast starting material for controlled expansion, cell transfection studies, viral proliferation research, and oncogene research. This product should be used as a research cell model, not as evidence of clinical performance, diagnostic utility, viral permissiveness, or a defined quantitative assay outcome.
-
ISRIB (trans-isomer): PERK Inhibitor Workflows
2026-09-13
ISRIB (trans-isomer) gives researchers a controlled way to separate stress-induced translation shutdown from upstream stress signaling. This workflow-focused guide connects eIF2B-centered ISR inhibition with ER stress, apoptosis assays, and memory-retention experiments, while emphasizing timing, controls, and interpretation limits.
-
CHIR-99021 for Wnt-Controlled Organoid Workflows
2026-09-12
CHIR-99021 (CT99021) gives researchers a selective, time-resolved way to manipulate GSK-3 and Wnt/β-catenin activity in stem-cell and organoid systems. This guide translates the compound into suspension human intestinal organoid workflows, with practical controls, readouts, and troubleshooting for mesothelial differentiation studies.
-
MMP-2 Liposomes for Sequential Cancer Immunotherapy
2026-09-11
The reference study developed NLG919@Lip-pep1, an MMP-2-responsive liposome that sequentially presents the PD-1 pathway-blocking peptide AUNP-12 and the IDO inhibitor NLG919. Its cascade-targeting design coordinated checkpoint relief with remodeling of the immunosuppressive breast cancer microenvironment, providing a useful preclinical framework for combination immunotherapy delivery.